Akash Anandraj

Akash Anandraj

Auto-generated profile, based on publicly available information

Akash Anandraj


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Bioresource Technology
Verified
Journal Article
Closed access
TMTaurai Mutanda
Taurai Mutanda
DRDESIKAN RAMESH
DESIKAN RAMESH
SKS. Karthikeyan
S. Karthikeyan
SKSheena Kumari
Sheena Kumari
AAA. Anandraj
A. Anandraj
FBFaizal Bux
Faizal Bux

1 January 2011 in Bioresource Technology
Verified
Journal Article
Closed access
SWS. White
S. White
AAA. Anandraj
A. Anandraj
FBFaizal Bux
Faizal Bux

1 December 2017 in Renewable and Sustainable Energy Reviews
Verified
Journal Article
Closed access
JBJoseph K. Bwapwa
Joseph K. Bwapwa
AAAkash Anandraj
Akash Anandraj
CTCristina Trois
Cristina Trois

1 May 2003 in Acta Oecologica
Verified
Journal Article
Closed access
RPRenzo Perissinotto
Renzo Perissinotto
CNChristian Nozais
Christian Nozais
IKIsrael Kibirige
Israel Kibirige
AAAkash Anandraj
Akash Anandraj

1 September 2002 in Marine Pollution Bulletin
Verified
Journal Article
Closed access
MGM.A Gregory
M.A Gregory
DMDavid Marshall
David Marshall
RGR.C George
R.C George
AAA Anandraj
A Anandraj
TMT.P McClurg
T.P McClurg

21 July 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
DNDevashan Naidoo
Devashan Naidoo
ARAyan Roy
Ayan Roy
PKPallab Kar
Pallab Kar
TMTaurai Mutanda
Taurai Mutanda
AAAkash Anandraj
Akash Anandraj
A novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) has emerged as the causative agent behind the coronavirus disease 2019 (COVID-19) pandemic. Treatment efforts have been severely impeded due to the lack of specific effective antiviral drugs for the treatment of COVID-associated pathologies. In the present research endeavour the inhibitory prospects of cyanobacterial metabolites were assessed at the active binding pockets of the two vital SARS-CoV-2 proteases namely, main protease (Mpro) and the papain-like protease (PLpro) that proteolytically process viral polyproteins and facilitate viral replication, employing an in silico molecular interaction-based approach. It was evident from our analysis based on the binding energy scores that the metabolites cylindrospermopsin, deoxycylindrospermopsin, carrageenan, cryptophycin 52, eucapsitrione, tjipanazole, tolyporphin and apratoxin A exhibited promising inhibitory potential against the SARS-CoV-2 Mpro. The compounds cryptophycin 1, cryptophycin 52 and deoxycylindrospermopsin were observed to display encouraging binding energy scores with the PLpro of SARS-CoV-2. Subsequent estimation of physicochemical properties and potential toxicity of the metabolites followed by robust molecular dynamics simulations and analysis of MM-PBSA energy scoring function established deoxycylindrospermopsin as the most promising inhibitory candidate against both SARS-CoV-2 proteases. Present research findings bestow ample scopes to further exploit the potential of deoxycylindrospermopsin as a successful inhibitor of SARS-CoV-2 in vitro and in vivo and pave the foundation for the development of novel effective therapeutics against COVID-19. Communicated by Ramaswamy H. Sarma